It has been identified as the first compound to act upstream of cryopyrin to prevent PAMPs, DAMPs, and crystal-induced IL-1β secretion (Lamkanfi et al., 2009) and reduce IL-1β and IL-8 production by PMNs in cases of bacterial infections in patients with diabetes (Kewcharoenwong et al., 2013). Here, NLRP3 is linked to bacterial infectious disease.